
Beijing SL Pharmaceutical Co., Ltd.
SZSE:002038.SZ
11.69 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 652.634 | 1,018.359 | 1,050.165 | 1,214.811 | 1,112.734 | 2,029.704 | 2,167.472 | 1,242.076 | 1,009.847 | 1,156.548 | 1,242.952 | 1,161.779 | 1,007.018 | 622.772 | 457.842 | 390.025 | 358.003 | 237.531 | 143.936 | 118.558 | 93.051 | 71.051 | 49.905 | 32.183 |
Cost of Revenue
| 211.533 | 187.787 | 156.956 | 183.574 | 163.422 | 417.379 | 448.275 | 364.31 | 351.265 | 393.589 | 372.427 | 378.621 | 330.306 | 153.115 | 106.742 | 66.984 | 49.036 | 81.626 | 53.128 | 45.907 | 32.458 | 20.647 | 11.511 | 4.773 |
Gross Profit
| 441.101 | 830.572 | 893.21 | 1,031.236 | 949.312 | 1,612.325 | 1,719.197 | 877.766 | 658.583 | 762.96 | 870.525 | 783.158 | 676.711 | 469.658 | 351.1 | 323.041 | 308.967 | 155.905 | 90.809 | 72.651 | 60.593 | 50.404 | 38.394 | 27.41 |
Gross Profit Ratio
| 0.676 | 0.816 | 0.851 | 0.849 | 0.853 | 0.794 | 0.793 | 0.707 | 0.652 | 0.66 | 0.7 | 0.674 | 0.672 | 0.754 | 0.767 | 0.828 | 0.863 | 0.656 | 0.631 | 0.613 | 0.651 | 0.709 | 0.769 | 0.852 |
Reseach & Development Expenses
| 149.623 | 177.107 | 161.649 | 196.147 | 188.641 | 128.353 | 72.894 | 73.682 | 55.02 | 92.301 | 58.787 | 88.389 | 73.972 | 59.882 | 58.181 | 0 | 0 | 40.805 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 11.293 | 12.731 | 23.499 | 15.546 | 19.398 | 23.564 | 11.108 | 11.26 | 14.264 | 12.761 | 14.511 | 18.289 | 12.239 | 5.256 | 2.807 | 63.871 | 59.917 | 8.219 | 31.163 | 29.183 | 17.025 | 11.586 | 10.935 | 4.914 |
Selling & Marketing Expenses
| 109.423 | 263.871 | 426.799 | 481.668 | 496.3 | 890.227 | 911.164 | 369.417 | 83.843 | 33.665 | 30.389 | 31.131 | 34.767 | 18.029 | 18.98 | 14.398 | 11.255 | 10.753 | 9.502 | 10.034 | 9.671 | 6.244 | 5.294 | 1.622 |
SG&A
| 120.715 | 276.603 | 450.299 | 497.215 | 515.698 | 913.79 | 922.272 | 380.677 | 98.107 | 46.426 | 44.9 | 49.42 | 47.006 | 23.285 | 21.787 | 78.269 | 71.173 | 18.972 | 40.665 | 39.216 | 26.697 | 17.83 | 16.23 | 6.535 |
Other Expenses
| 298.151 | -102.028 | 99.247 | 82.729 | 75.57 | 66.4 | -9.991 | 0.997 | 20.181 | 11.933 | 32.444 | 19.272 | 5.249 | 11.409 | 37.977 | 10.184 | 6.986 | 9.633 | 2.344 | 0.961 | 0.543 | 0.693 | -0.038 | 0.062 |
Operating Expenses
| 568.49 | 352.702 | 711.195 | 776.091 | 779.909 | 1,108.544 | 1,050.135 | 490.857 | 196.177 | 186.169 | 147.12 | 175.354 | 158.824 | 103.667 | 93.389 | 83.008 | 75.671 | 62.018 | 41.936 | 40.115 | 27.414 | 18.293 | 16.584 | 6.725 |
Operating Income
| -119.603 | 477.87 | 263.317 | 457.545 | 412.881 | 560.901 | 681.637 | 621.623 | 507.181 | 656.816 | 780.477 | 654.627 | 555.09 | 593.043 | 281.576 | 262.859 | 228.997 | 139.45 | 57.433 | 38.414 | 35.312 | 33.21 | 21.847 | 20.623 |
Operating Income Ratio
| -0.183 | 0.469 | 0.251 | 0.377 | 0.371 | 0.276 | 0.314 | 0.5 | 0.502 | 0.568 | 0.628 | 0.563 | 0.551 | 0.952 | 0.615 | 0.674 | 0.64 | 0.587 | 0.399 | 0.324 | 0.379 | 0.467 | 0.438 | 0.641 |
Total Other Income Expenses Net
| -14.146 | -12.976 | -3.965 | 0.292 | -0.101 | -0.013 | -9.991 | 0.997 | 20.181 | 11.929 | 31.938 | 19.046 | 43.236 | 240.477 | 61.963 | 34.287 | 6.986 | 9.633 | 3.591 | 4.917 | 1.529 | -0.186 | 0 | 0 |
Income Before Tax
| -133.75 | 464.894 | 259.352 | 457.837 | 412.779 | 560.888 | 671.646 | 622.62 | 527.363 | 668.745 | 812.415 | 673.674 | 560.339 | 604.452 | 319.553 | 273.043 | 235.983 | 149.084 | 58.188 | 38.414 | 35.282 | 33.024 | 21.847 | 20.623 |
Income Before Tax Ratio
| -0.205 | 0.457 | 0.247 | 0.377 | 0.371 | 0.276 | 0.31 | 0.501 | 0.522 | 0.578 | 0.654 | 0.58 | 0.556 | 0.971 | 0.698 | 0.7 | 0.659 | 0.628 | 0.404 | 0.324 | 0.379 | 0.465 | 0.438 | 0.641 |
Income Tax Expense
| -58.463 | 49.937 | 31.01 | 36.51 | 51.326 | 81.39 | 108.252 | 93.862 | 79.977 | 91.528 | 111.368 | 101.661 | 80.361 | 80.061 | 43.168 | 29.295 | 17.556 | 14.259 | 7.847 | 4.571 | 3.289 | 1.826 | 2.553 | 1.719 |
Net Income
| -74.066 | 416.692 | 234.404 | 425.94 | 364.709 | 486.784 | 571.45 | 533.575 | 452.108 | 575.049 | 695.083 | 577.397 | 481.011 | 523.345 | 272.714 | 244.105 | 217.859 | 134.801 | 50.321 | 33.821 | 32.002 | 31.2 | 19.294 | 18.904 |
Net Income Ratio
| -0.113 | 0.409 | 0.223 | 0.351 | 0.328 | 0.24 | 0.264 | 0.43 | 0.448 | 0.497 | 0.559 | 0.497 | 0.478 | 0.84 | 0.596 | 0.626 | 0.609 | 0.568 | 0.35 | 0.285 | 0.344 | 0.439 | 0.387 | 0.587 |
EPS
| -0.07 | 0.41 | 0.23 | 0.41 | 0.36 | 0.47 | 0.83 | 0.52 | 0.44 | 0.56 | 0.68 | 0.56 | 0.47 | 0.51 | 0.27 | 0.24 | 0.22 | 0.13 | 0.048 | 0.034 | 0.032 | 0.043 | 0.033 | 0.032 |
EPS Diluted
| -0.07 | 0.41 | 0.23 | 0.41 | 0.36 | 0.47 | 0.83 | 0.52 | 0.44 | 0.56 | 0.68 | 0.56 | 0.47 | 0.51 | 0.27 | 0.24 | 0.21 | 0.13 | 0.047 | 0.034 | 0.032 | 0.043 | 0.033 | 0.032 |
EBITDA
| 196.726 | 598.37 | 363.784 | 539.847 | 492.843 | 644.613 | 735.52 | 424.398 | 487.759 | 609.535 | 863.736 | 685.735 | 538.218 | 383.593 | 271.39 | 252.383 | 247.835 | 159.012 | 62.791 | 48.383 | 44.457 | 41.009 | -16.584 | 20.709 |
EBITDA Ratio
| 0.301 | 0.588 | 0.346 | 0.444 | 0.443 | 0.318 | 0.339 | 0.342 | 0.483 | 0.527 | 0.695 | 0.59 | 0.534 | 0.616 | 0.593 | 0.647 | 0.692 | 0.669 | 0.436 | 0.408 | 0.478 | 0.577 | -0.332 | 0.643 |